Objective: To study the expressions of C-C class chemokine 17 (CCL17), C-C class chemokine 22 (CCL22), and C-C chemokine receptor 4 (CCR4) in newly diagnosed multiple myeloma (NDMM) for analyzing their correlations with clinical features and to preliminarily explore their roles in the development of NDMM. Methods: The study included 40 patients with NDMM and 20 healthy volunteers from the Department of Hematology of the Affiliated Hospital of Zunyi Medical University from July 2020 to December 2022. Peripheral blood, bone marrow, and bone marrow biopsy tissue samples were collected from the two groups. The expression levels of CCL17, CCL22, and CCR4 in patients with NDMM were analyzed using real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR), enzyme-linked immunosorbent assay (ELISA), and immunohistochemistry. The mRNA expression levels of CCL17, CCL22, and CCR4 in the bone marrow mononuclear cell (BMMNC) of patients with NDMM were analyzed to assess their correlations with clinical indicators. Results: The mRNA expression levels of CCL17, CCL22, and CCR4 in BMMNC were higher in patients with NDMM than in controls (all P<0.05). The protein expression levels of CCL17 and CCL22 in peripheral blood supernatants and bone marrow supernatants were higher in patients with NDMM than in controls (all P<0.05). The expression levels of CCL17, CCL22, and CCR4 in bone marrow biopsy tissues were higher in patients with NDMM than in controls (all P<0.05). The mRNA expression level of CCL17 was increased in NDMM patients with combined anemia, bone damage, renal damage, and M protein level ≥30 g/L (all P<0.05). The mRNA expression level of CCL22 was increased in NDMM patients with combined anemia, bone damage, and renal damage (all P<0.05). The mRNA expression level of CCR4 was increased in NDMM patients with combined anemia and renal damage (all P<0.05) . Conclusion: CCL17, CCL22, and CCR4 were highly expressed in clinical samples from patients with NDMM compared to those from controls, and they may be involved in the occurrence and development of NDMM.
目的： 研究CCL17、CCL22及CCR4在新诊断多发性骨髓瘤（NDMM）中的表达情况，分析其与临床特征的相关性，初步探讨其在NDMM发生发展中的作用。 方法： 选取2020年7月至2022年12月在遵义医科大学附属医院血液内科就诊的40例NDMM患者以及20名健康志愿者作为研究对象，收集两组外周血、骨髓及骨髓活检组织样本并通过RQ-PCR、ELISA、免疫组化检测NDMM患者的CCL17、CCL22以及CCR4的表达水平。分析NDMM患者骨髓单个核细胞（BMMNC）中CCL17、CCL22及CCR4的mRNA表达水平与患者临床指标的相关性。 结果： NDMM患者BMMNC中CCL17、CCL22及CCR4的mRNA表达水平均高于健康志愿者（对照组）（P值均<0.001）；NDMM患者外周血上清和骨髓上清中CCL17、CCL22的蛋白表达水平均高于对照组（P值均<0.001）；NDMM患者骨髓活检组织中CCL17、CCL22及CCR4的表达水平均高于对照组（P值均<0.05）。CCL17 mRNA在合并贫血、骨质损害、肾损害以及单克隆免疫球蛋白≥30 g/L的NDMM患者中表达水平上升（P值均<0.05）；CCL22 mRNA在合并贫血、骨质损害、肾损害的NDMM患者中表达水平上升（P值均<0.05）；CCR4 mRNA在合并贫血、肾损害的NDMM患者中表达水平上升（P值均<0.05）。 结论： 与对照组相比，CCL17、CCL22及CCR4在NDMM患者临床样本中均呈高表达，可能参与了NDMM的发生及发展。.
Keywords: CCL17; CCL22; CCR4; Multiple myeloma; Tumorigenesis.